Middle East and Africa Blood Screening Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Blood Screening Market Size

• The Middle East and Africa blood screening market size was valued at USD 619.73 million in 2025 and is expected to reach USD 1,221.32 million by 2033, at a CAGR of 8.85% during the forecast period
• The market growth is largely fueled by increasing prevalence of infectious diseases, rising awareness about blood safety, and the expansion of healthcare infrastructure across the region, driving demand for advanced blood screening technologies
• Furthermore, growing government initiatives to improve blood transfusion safety, coupled with rising adoption of automated and high-throughput screening systems, are positioning blood screening as a critical component of modern healthcare. These converging factors are accelerating the uptake of blood screening solutions, thereby significantly boosting the industry's growth

Middle East and Africa Blood Screening Market Analysis

• Blood screening, encompassing serological and molecular testing of donated blood for infectious diseases, is becoming a critical component of modern healthcare infrastructure in both public and private sectors due to its ability to ensure transfusion safety, reduce disease transmission, and improve patient outcomes
• The rising demand for blood screening is primarily driven by increasing prevalence of infectious diseases, heightened awareness regarding blood safety, and growing adoption of automated and high-throughput screening technologies in hospitals and blood banks
• Egypt dominated the Middle East and Africa blood screening market with the largest revenue share of 38.7% in 2025, supported by expanding healthcare infrastructure, government-led blood safety initiatives, and rising collaborations between local blood banks and global diagnostics companies, with substantial growth in screening volumes due to modernization of blood transfusion services
• Saudi Arabia is expected to be the fastest-growing country in the blood screening market during the forecast period, driven by rising healthcare expenditure, increasing private healthcare adoption, and implementation of advanced nucleic acid testing (NAT) technologies
• Nucleic Acid Test segment dominated the market with a share of 45.3% in 2025, owing to its superior sensitivity and specificity in detecting viral infections such as HIV, HBV, and HCV, enabling safer transfusions and reducing the window period compared to conventional serology tests

Report Scope and Middle East and Africa Blood Screening Market Segmentation

Middle East and Africa Blood Screening Market Trends

“Adoption of Advanced Nucleic Acid Testing (NAT) and Automation”

• A significant and accelerating trend in the Middle East and Africa blood screening market is the growing implementation of automated NAT systems and high-throughput screening technologies, which enhance the accuracy and speed of detecting infectious diseases in donated blood
• For instance, the Roche cobas® 6800 system has been deployed in several blood banks across Egypt and South Africa, enabling simultaneous high-volume testing for HIV, HBV, and HCV with minimal manual intervention
• NAT integration allows earlier detection of infections during the window period, reducing the risk of transfusion-transmitted infections and ensuring higher safety standards for patients. For instance, some Grifols platforms utilize automation to reduce human error and improve sample processing efficiency across multiple donor units
• The seamless incorporation of automated blood screening into existing laboratory workflows enables centralized management of testing processes, reporting, and quality control, improving overall operational efficiency in hospitals and blood centers
• This trend toward more sensitive, rapid, and automated testing solutions is fundamentally reshaping the blood safety landscape. Consequently, companies such as Abbott are developing NAT-enabled platforms with multiplex testing capabilities and automated reporting systems
• The demand for high-throughput, automated blood screening solutions is growing rapidly across both public and private healthcare sectors, as governments and healthcare providers prioritize patient safety and operational efficiency
• Another trend is the adoption of portable and rapid point-of-care testing devices for blood safety in remote and underserved regions, enabling timely screening and reducing dependency on centralized laboratories. For instance, Bio-Rad’s rapid NAT kits are being trialed in mobile blood donation units in Nigeria and Kenya

Middle East and Africa Blood Screening Market Dynamics

Driver

“Increasing Prevalence of Infectious Diseases and Blood Safety Awareness”

• The rising incidence of infectious diseases such as HIV, HBV, and HCV, coupled with growing awareness regarding transfusion safety, is a significant driver for the heightened adoption of advanced blood screening technologies
• For instance, in March 2025, the Egyptian Ministry of Health implemented NAT testing in major urban blood banks to enhance early detection of viral infections among donors
• As healthcare providers become more aware of the risks of transfusion-transmitted infections, blood screening solutions offer advanced capabilities such as multiplex testing, early pathogen detection, and automated quality control, providing a compelling upgrade over traditional serology methods
• Furthermore, government initiatives promoting safer blood donation practices and mandatory screening protocols are making advanced blood screening an integral component of national healthcare strategies, ensuring higher reliability and safety of transfusions
• The ability to rapidly screen large donor populations, reduce the window period for infection detection, and provide real-time results are key factors propelling the adoption of blood screening solutions across hospitals, blood banks, and diagnostic laboratories
• Increasing partnerships between local healthcare providers and global diagnostics companies are also driving technology transfer and training programs, improving adoption rates of modern screening platforms. For instance, collaborations between Abbott and South African blood services are enhancing laboratory capabilities
• Another driving factor is rising investment in healthcare infrastructure by GCC countries, such as Saudi Arabia and UAE, focusing on modernizing blood banks and integrating NAT-based automated screening systems to ensure safer transfusions

Restraint/Challenge

“High Cost and Infrastructure Limitations”

• The relatively high cost of advanced blood screening technologies, including NAT platforms, and the need for specialized laboratory infrastructure pose a significant challenge to broader adoption across Middle East and Africa
• For instance, some smaller clinics and rural blood banks in sub-Saharan Africa have delayed the implementation of automated screening due to budget constraints and limited access to trained personnel
• Addressing these financial and infrastructural challenges through cost-effective solutions, public-private partnerships, and donor-funded programs is crucial for expanding market penetration. For instance, companies such as Grifols offer modular NAT systems that can be scaled according to laboratory capacity to reduce upfront investment
• Additionally, logistical hurdles, including electricity reliability, maintenance requirements, and supply chain limitations for reagents and consumables, can hinder consistent operation of automated blood screening systems
• Overcoming these challenges through affordable technology options, capacity-building programs, and government-supported funding initiatives will be vital for sustained growth of the blood screening market in the region
• Limited technical expertise and shortage of trained laboratory personnel in remote areas can delay the adoption and efficient operation of sophisticated blood screening platforms. For instance, some regional blood banks in Nigeria require external training support to operate NAT systems effectively
• Regulatory variations and delays in approvals for new screening technologies across different Middle East and Africa countries can impede market expansion. For instance, approval processes for automated NAT devices vary between Egypt, South Africa, and Kenya, affecting timely deployment

Middle East and Africa Blood Screening Market Scope

The market is segmented on the basis of products and services, technology, disease type, and end user.

• By Products and Services

On the basis of products and services, the market is segmented into reagents and kits, instruments, software and services. The reagents and kits segment dominated the market with the largest revenue share in 2025, driven by their essential role in detecting a wide range of infectious diseases and ensuring blood safety. Reagents and kits are highly consumable, requiring frequent replenishment, which contributes to recurring revenue for suppliers. Hospitals, blood banks, and diagnostic centers prefer reliable and validated kits for routine screening, which enhances workflow efficiency. The segment benefits from continuous innovation, including multiplex kits capable of detecting multiple pathogens simultaneously. Additionally, the increasing prevalence of HIV, HBV, HCV, and emerging infectious diseases in the region is further boosting demand. Vendors like Roche and Abbott provide region-specific kits optimized for local epidemiology.

The instruments segment is expected to witness the fastest growth during the forecast period, driven by the rising adoption of automated and high-throughput screening systems. Instruments such as NAT analyzers, ELISA readers, and automated sample processors improve accuracy and reduce human error. The growing focus on laboratory modernization in countries like Saudi Arabia, Egypt, and South Africa is accelerating instrument deployment. Increasing investments in healthcare infrastructure and funding from government initiatives for safer blood transfusions are further supporting growth. Moreover, integration of instruments with laboratory information management systems (LIMS) enhances workflow efficiency and data management. Instruments also support multiplex testing, reducing the overall time and cost per sample.

• By Technology

On the basis of technology, the market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, Western blot assay, next-generation sequencing (NGS), and others. The Nucleic Acid Test (NAT) segment dominated the market with the largest share of 45.3% in 2025, owing to its high sensitivity and specificity in detecting blood-borne viruses such as HIV, HBV, and HCV. NAT reduces the window period of infection, ensuring safer transfusions. Adoption of NAT is particularly strong in urban hospitals and major blood banks across Egypt, South Africa, and the UAE. Government mandates and international accreditation requirements for NAT further drive demand. The technology’s ability to process multiple samples simultaneously enhances operational efficiency. Vendors continuously innovate NAT platforms to include multiplex testing and automation features.

The rapid tests segment is expected to witness the fastest growth during the forecast period, driven by their ease of use, affordability, and suitability for remote or resource-limited settings. Rapid tests provide immediate results, making them ideal for small clinics, mobile blood donation units, and field-based screening programs. Countries with limited laboratory infrastructure, such as Kenya and Nigeria, are adopting rapid tests for efficient early detection of infections. The growing demand for point-of-care diagnostics and the increasing number of blood donation drives are further fueling adoption. Rapid test kits require minimal training and equipment, making them highly scalable across diverse healthcare settings. Continuous innovation in sensitivity and specificity also supports their expanding use in the region.

• By Disease Type

On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases, and others. The infectious diseases segment dominated the market with the largest revenue share in 2025, due to high prevalence of HIV, HBV, HCV, and malaria in the Middle East and Africa. Blood screening for infectious diseases is critical for transfusion safety and controlling outbreaks. Hospitals and blood banks prioritize testing for infectious pathogens, driving demand for NAT and ELISA-based solutions. Government initiatives and international funding programs further emphasize infectious disease screening. Rising public awareness regarding blood-borne infections also supports routine screening practices. Companies continue to introduce multiplex panels targeting multiple pathogens, enhancing adoption.

The HIV/AIDS segment is expected to witness the fastest growth during the forecast period, driven by high disease burden in sub-Saharan Africa and increasing government-supported testing initiatives. Early detection of HIV among blood donors is critical for safe transfusions and public health monitoring. Rapid and automated screening platforms are being increasingly deployed in high-prevalence regions. International aid and national health programs are funding large-scale HIV screening campaigns, creating strong market demand. The segment benefits from continuous innovation in rapid HIV tests and NAT platforms. Integration of testing programs with national healthcare databases supports real-time monitoring and reporting.

• By End User

On the basis of end user, the market is segmented into diagnostic centers, blood banks, hospitals, clinics, and ambulatory surgical centers. The blood bank segment dominated the market with the largest revenue share in 2025, as these facilities are the primary sites for donor blood collection, testing, and storage. Blood banks require high-throughput, reliable, and validated screening solutions to ensure safe transfusions. Investments in modern blood banks with NAT-enabled automation are increasing in Egypt, South Africa, and the GCC countries. Regulatory mandates for mandatory testing of all donor units further drive demand. Blood banks also benefit from long-term supplier contracts for reagents, kits, and instruments, providing consistent revenue streams. Advanced software and service offerings integrated with instruments enhance efficiency and traceability.

The diagnostic centers segment is expected to witness the fastest growth during the forecast period, driven by the increasing number of private diagnostic labs offering blood screening services in urban centers. Diagnostic centers cater to hospitals, clinics, and direct consumers, increasing the volume of blood samples tested. Rising awareness among patients about blood safety and preoperative screening is boosting demand. Adoption of automated and multiplex testing platforms enables faster turnaround times and higher accuracy. Growth of medical tourism in the GCC countries also supports the expansion of diagnostic center services. Integration with LIMS and cloud-based reporting enhances workflow efficiency and data management, making diagnostic centers an attractive growth segment.

Middle East and Africa Blood Screening Market Regional Analysis

• Egypt dominated the Middle East and Africa blood screening market with the largest revenue share of 38.7% in 2025, supported by expanding healthcare infrastructure, government-led blood safety initiatives, and rising collaborations between local blood banks and global diagnostics companies, with substantial growth in screening volumes due to modernization of blood transfusion services
• Healthcare providers and blood banks in the region prioritize reliable and automated screening solutions to reduce the risk of transfusion-transmitted infections, ensuring patient safety and compliance with international standards
• This widespread adoption is further supported by rising prevalence of infectious diseases, growing public awareness about blood safety, and the increasing implementation of high-throughput and NAT-based screening technologies, establishing blood screening as a critical healthcare service in both urban hospitals and major blood centers

The Egypt Blood Screening Market Insight

The Egypt blood screening market captured the largest revenue share of 38.7% in 2025, fueled by substantial investments in modern healthcare infrastructure and government initiatives to ensure safe blood transfusions. Hospitals and blood banks are increasingly adopting NAT-based automated screening technologies to reduce the risk of transfusion-transmitted infections. The growing prevalence of infectious diseases such as HIV, HBV, and HCV, coupled with rising public awareness about blood safety, is further propelling market growth. Additionally, collaborations with global diagnostics companies are enhancing the availability of advanced reagents, kits, and instruments. The integration of automated testing platforms with laboratory information management systems (LIMS) is improving workflow efficiency and data traceability across blood centers.

South Africa Blood Screening Market Insight

The South Africa blood screening market is projected to expand at a substantial CAGR during the forecast period, driven by increasing government-led health programs and rising adoption of advanced screening technologies. The country’s focus on strengthening blood safety protocols and upgrading public and private blood banks is fostering the adoption of automated NAT and ELISA systems. Rising prevalence of infectious diseases and ongoing national campaigns for safe blood donation are also key growth drivers. Diagnostic laboratories and hospitals are incorporating high-throughput systems to process large volumes of samples efficiently. Moreover, awareness programs targeting healthcare professionals and donors are supporting increased uptake of blood screening services.

Nigeria Blood Screening Market Insight

The Nigeria blood screening market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the rising incidence of transfusion-transmitted infections and government initiatives to improve blood safety. Private and public healthcare facilities are increasingly implementing rapid tests and ELISA-based solutions to enhance early detection of pathogens. Investments in mobile blood donation units and regional blood centers are supporting expanded screening coverage. The growing population and urbanization are boosting demand for reliable screening services. International collaborations and donor-funded programs are also facilitating access to modern testing technologies. Additionally, Nigeria’s increasing focus on point-of-care and portable testing systems is improving screening efficiency in remote areas.

Saudi Arabia Blood Screening Market Insight

The Saudi Arabia blood screening market is expected to expand at a considerable CAGR during the forecast period, fueled by rising healthcare expenditure and modernization of hospital laboratories. Government initiatives aimed at enhancing national blood safety standards are promoting the adoption of high-throughput and automated NAT testing systems. Hospitals and blood banks are increasingly integrating digital reporting platforms to improve traceability and compliance. The growing prevalence of infectious diseases, coupled with mandatory screening regulations, is further boosting demand. Saudi Arabia’s investment in public-private partnerships for healthcare infrastructure also supports market growth. Increased awareness and training programs for laboratory personnel are ensuring efficient utilization of advanced screening technologies.

Middle East and Africa Blood Screening Market Share

The Middle East and Africa Blood Screening industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Thermo Fisher Scientific (U.S.)
• Bio-Rad Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• BIOMÉRIEUX (France)
• Beckman Coulter (U.S.)
• SD BIOSENSOR (South Korea)
• Fujirebio (Japan)
• Ortho Clinical Diagnostics (U.S.)
• QIAGEN (Netherlands)
• Sysmex Corporation (Japan)
• Mindray (China)
• DiaSorin (Italy)
• Hologic (U.S.)
• Meridian Bioscience (U.S.)
• Illumina (U.S.)
• Agilent Technologies (U.S.)
• PerkinElmer (U.S.)
• Hangzhou Biotest Biotech Co., Ltd. (China)

What are the Recent Developments in Middle East and Africa Blood Screening Market?

• In November 2025, the People’s Republic of China announced a USD 3.49 million funding partnership with South Africa, facilitated by UNAIDS, to expand HIV services including testing, prevention outreach, and support for populations at high risk such as people who inject drugs. This initiative aims to strengthen HIV screening and diagnostic coverage in South Africa
• In July 2025, the Ministry of Health in the Democratic Republic of the Congo, supported by the World Health Organization (WHO), implemented an integrated testing model that combines rapid HIV and syphilis screening within mpox response centers. This model expanded comprehensive testing services in low‑resource settings, increased detection rates, and helped connect individuals to treatment
• In April 2025, the Kenyan government announced a nationwide rollout of whole blood automation technology to modernize transfusion services, significantly improving processing efficiency, extending red blood cell shelf life, and boosting safety standards in regional blood centers. This initiative aims to reduce wastage, increase quality assurance, and support more reliable blood supply management across the country
• In April 2025, a major community‑led report raised alarms about a surging HIV epidemic in the Middle East and North Africa (MENA), particularly citing sharp increases in new infections, underscoring the urgent need for enhanced testing, screening, and diagnostic efforts including improved blood safety practices
• In March 2025, reports highlighted that the Ghana National Blood Service (GNBS) will establish blood centers in all 16 regions of the country, enhancing accessibility to safe blood and improving collection and distribution networks to ensure that no patient dies from lack of blood. This strategic expansion underscores efforts to strengthen transfusion services in West Africa

SKU-26812